Trial intelligence / Profile preview

Extension phase II study of imatinib in adults with Philadelphia chromosome–positive leukemias

2005-001381-14Phase 2Completed

Sponsor
Novartis
Start
Jun 2005
Modality
Small Molecules
Countries
1
01

Overview

Phase 2, open-label, single-arm trial of imatinib in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and chronic myelogenous leukemia (CML), sponsored by Novartis. Primary endpoint: Overall survival. Started Jun 2005; status: completed.

02

Drugs

03

Conditions

acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)chronic myelogenous leukemia (CML)

Beyond the preview

Go deeper on 2005-001381-14.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2005-001381-14.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call